To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Resverlogix Presents at Biotech Showcase During JP Morgan Week
Resverlogix Corp. has announced that Donald McCaffrey, president and chief executive officer presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week. The presentation can be accessed via the following link: http://edge.media-server.com/m/p/5wz2z9gn.
Mr. McCaffrey was excited to share developments of the Company's proposed new phase 3 clinical trial BETONMACE. "This trial represents an unprecedented opportunity to reduce major adverse coronary events "MACE" in patients with diabetes. RVX-208 is the only selective BET-Bromodomain inhibitor in clinical trials to reduce the risk of death by cardiac events in patients with CVD and diabetes."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
